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Introduction: Lymph nodal involvement in papillary thyroid cancers is very common, but the role of
lymph node dissection is still controversial. Surgeons are consequently divided between opposed to and
in favor of routine central neck dissection associated with total thyroidectomy.
Methods: Clinical records of 210 patients undergoing from January 2000 to December 2006 total thy-
roidectomy without routine lymph node dissection were retrospectively evaluated. One hundred and
ninety eight patients (94.2%) underwent radioiodine ablation as well, followed by Thyroid Stimulating
Hormone suppression therapy. In patients with loco regional lymph nodal recurrence, central (VI) and
ipsilateral (IIIeIV) lymph node dissection was performed.
Results: Incidence of permanent hypoparathyroidism (iPTH < 10 pg/ml) and permanent vocal fold pa-
ralysis were respectively 1.4% and 1.9%. After an 8-year mean follow-up, the rate of loco regional
recurrence was 4.2%e9/210 patients. In these cases selective lymph node dissection was carried out
without complications.
Discussion: The role of neck dissection in papillary thyroid cancer management, is still subject of research
and controversial regarding routine or therapeutic indications, surgical extension, its impact on local
recurrence and survival.
Conclusion: A low loco regional recurrence rate may be observed after total thyroidectomy without
prophylactic lymph node dissection. Lymph nodal recurrences were more frequent in young male pa-
tients, sometime affected by follicular variant, in each case less than 2 cm. There is a general agreement
about the extension of therapeutic lymph node dissection, while routine central neck dissection is still
controversial and may be indicated in high risk patients.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
In the management of papillary thyroid cancer (PTC), after
considering the multifocal nature of this neoplasm [1], the effec-
tiveness of radioactive iodine (RAI) treatment and thyroglobulin
(Tg) serum levels during follow-up, there is a substantial agreement
about total thyroidectomy (TT) and Thyroid Stimulating Hormone
(TSH) suppression therapy. On the contrary, the role of lymph node
dissection (LD), regarding its indication- routine or therapeutic-,
extension e ipsi or contralateral- and outcomes, in terms of
recurrence and survival, is still controversial. According to thezo).
f of Surgical Associates Ltd.recent American Thyroid Association (ATA) guide lines, routine
central lymph node dissection (RCLD) is indicated in high risk pa-
tients with advanced primary tumors [2], while Udelsman et al.
concluded that, to evaluate its beneﬁts, prospective randomized
trials are needed [3]. Prevention of a further recurrence, the high
risk of positive lymph nodes and the lower morbidity rate of the
ﬁrst operation are evocated in favor of RCLD [4], often associated
with a higher rate of complications, without demonstrable beneﬁts
in terms of long-term survival [5,6]. PTC “low aggressive behavior”,
demonstrated by low loco regional recurrence and mortality rates,
makes analysis of the outcomes difﬁcult. In an attempt to better
clarify the impact of LD in treating PTC, we analyzed the clinico-
pathological pattern in nine patients with lymph nodal recurrence.
Selective LD is indicated in case of metastatic lymph node, but,
according to our experience, RCLD beneﬁts, in absence of lymph
Table 1
Demographic and pathological data of the 210 PTC patients.
Patients Male 14.2%
Female 85.7%
Mean age 42 years
Histology Classic 81%
Follicular-variant 13.3%
Hürthle cell e variant 3.8%
Tall cell e variant 0.9%
Tumor Mean size 1.4 cm
Unique 84.8%
Multifocal 15.2%
Microcarcinoma 29%
Loco regional inﬁltration 11.4%
pTNM stage I 61.4%
II 32.3%
III 6.1%
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RAI ablation allows favorable long-term results regarding recur-
rence and survival, as well as the role of routine LD needs to be
more intensively investigated.
2. Methods
Clinical records of PTC patients, undergoing TT without LD, be-
tween January 2000 and December 2006, in absence of suspicious
enlarged lymph nodes at preoperative ultrasonography and intra-
operative inspection were analyzed. Patients undergone TT asso-
ciated with LD during the same period were excluded from the
study, as well as incidentally removed perithyroidal nodes in the
specimens were considered criteria of exclusion. In every case, a
preoperative diagnosis of PTC was obtained by US guided FNC. The
preoperative work-up consisted of thyroid hormones, TSH, Tg and
anti-Tg antibodies levels evaluation, and a high resolution ultra-
sonography of the neck. A pre-and postoperative ﬁbrolaryngoscopy
was performed in all patients. In thirty-six patients (17%), BRAF
mutations were searched on tumor specimens. Tumor extent was
evaluated according to the American Joint Committee on Cancer
(AJCC) TNM.
Classiﬁcation of Thyroid Cancer (7th edition, 2010). Post-
operative diagnosis of lymph node recurrence was detected by US
guided FNC and Tg washing of FNC aspirates, performed in case of
enlarged lymph node1 cm. Patient demographics, postoperative
complications, including neck hematoma requiring reoperation,
transient or permanent hypoparathyroidism, transient or per-
manent vocal cord palsy, distant and loco regional recurrence,
detected by postoperative surveillance, were recorded. In case of a
iPTH level <10 pg/ml (normal value ¼ 10e65), hypoparathyroid-
ism was determined, and it was considered permanent if per-
sisting for more than 6 months and requiring medical therapy.
Vocal fold palsy, conﬁrmed by ﬁbrolaryngoscopy, was considered
permanent when lasting for more than 6 months. Tg and TSH was
determined by Immunite immunoassay (Siemens Healthcare Di-
agnostics) with sensitivities of 0.2 ng/ml and 0.03 mIU/L,
respectively. Anti-Tg antibodies were detected by Quanta Lite
enzyme-linked immunosorbent assay (Inova Diagnostics), and we
considered 40 UI/ml as cut-off value of Anti-Tg Abs (normal
value ¼ 0e60 UI/ml). Each surgeon participating to the study used
a similar technique in performing TT, as well as central and lateral
lymph node dissection. An ultrasonic scalpel, Harmonic Ace®
(Ethicon Endosurgery) was utilized in 35 cases, and in selected
cases hemostasis was optimized by means of Floseal® Hemostatic
Matrix (Baxter Zurich e Switzerland). Routinely, recurrent
laryngeal nerves were identiﬁed and exposed, as well as para-
thyroid glands were identiﬁed and preserved. In case of suspected
devascularized or incidentally removed parathyroid glands, a
muscular autoimplantation followed. Serum calcium and intact
parathormone levels were assayed on the ﬁrst postoperative day,
and subsequently on a clinical basis evaluation. In case of post-
operative loco regional recurrence, a selective central and ipsi-
lateral (VI, III, IV) lymph node dissectionwas performed according
to the American Academy of Otolaryngology e Head and Neck
Surgery [7]. After surgery, 198 patients (94.2%) underwent adju-
vant RAI ablation (1850-3700 MBq-131I). Apart from lymph node
involvement, indications for postoperative 131I treatment are a
tumor >1.0 cm, extra-capsular thyroid invasion or loco regional
extension, an unfavorable histological subtype (follicular, diffuse
sclerosing, or tall cells papillary cancer), multifocal disease, BRAF-
positive tumor specimens. To obtain adequate levels of endoge-
nous TSH (>30 mU/ml), that are associated with an increased
radioiodine uptake, patients stopped L-T4 replacement 3e4
weeks before radioiodine treatment; when L-T4 withdrawal wasnot indicated, TSH stimulation was achieved with Recombinant
Human Thyrotropin (rhTSH) (Thyrogen®e Genzyme corporation).
Post-therapy whole-body scan was performed 4e7 days after RAI
treatment. Neck ultrasonography and monitoring of serum Tg and
Tg-antibodies levels were carried out every 6 months during
suppressive L-tiroxine treatment. A serum Tg level 1 ng/ml was
considered as undetectable. Surveillance for possible recurrence
in patients considered disease-free was achieved by Tg detection
after rhTSH stimulation (American Thyroid Association Guidelines
2009) and neck ultrasound. Diagnosis of disease recurrence in the
cervical lymph nodes was based on US-guided FNC, Tg washing of
FNC aspirates and serum Tg levels monitoring. The most recent
guide lines were considered and LD beneﬁts, complications and
impact on loco regional recurrence rate, and mortality were
evaluated. Qualitative data were expressed in percentage, while
quantitative data as means.
3. Results
Two hundred and ten PTC patients, 180 women and 30 men (F/
M ratio¼ 6/1), with a 42-yearmean age (14e79), were submitted to
TT (Table 1). In 19 patients (9%), parathyroid tissue was implanted
in the strap muscles, and in 23/210 cases (10.9%) parathyroid tissue
was identiﬁed in the ﬁnal pathology analysis. Incidence of surgical
complications is reported in Table 2. In one patient (0.4%) a neck
hematoma, requiring surgical re-exploration, was observed. The
mean tumor size was 1.4 cm (0.7e2.4), and a microcarcinoma
(1 cm) was diagnosed in 61 patients (29%). Histotype was classic
in 172 patients (81.9%), follicular variant in 28 (13.3%), Hürthle cells
in 8 (3.8%), tall cells in 2 (0.9%). Thirty-two patients (15.2%) had
multifocal tumors e 24 classic variant, 8 follicular variant. Twenty-
four patients (11.4%) had a loco regional inﬁltration (T3) by classic
variant tumor in 19 cases and by follicular variant tumor in 5 cases.
A BRAF mutation was discovered in 21 out of 36 tested patients
(58.3%). pTNM stage of the patients and pathological data are
shown in Table 1. No patient developed distant recurrence during
an 8-year mean follow-up (6e13).
After TT and RAI ablation, 9 cases (4.2%) of nodal recurrence e 6
central recurrences (VI) and 3 ipsilateral recurrences (IIIeIV) e
were observed. Demographic characteristics were the following:
ﬁve males e median age 42 years (18e79) e and 4 females e
median age 34 years (22e68) with a M/F ratio ¼ 1/0.8. The median
elapsed time between TT and lymph node recurrence was 28
months (12e82). Seven patients had classic variant, two had
follicular variant PTC (BRAF mutation was not evaluated); median
Tg value was 6.4 ng/ml (0.2e16 ng/ml) (Tg > 2 ng/ml in 7 patients
and <2 ng/ml in 2 patients) and Tg-antibodies value was >40 UI/ml
in 6 patients and <40 UI/ml in 3 (range 5.6e1852 UI/ml). In each
Table 2
Total Thyroidectomy: complications.
% N. Pts
Temporary Hypoparathyroidism 8.5 18/210
Permanent Hypoparathyroidism 1.4 3/210
Parathyroid tissue in the specimen 10.9 23/210
Temporary unilateral vcp 2.3 5/210
Permanent unilateral vcp 1.9 4/210
Bilateral vcp 0 0/221
Neck hematoma 0.47 1/210
VCP ¼ vocal cord palsy.
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IV) was performed, followed by another session of metabolic
radiotherapy. Signiﬁcant perioperative complications were not
observed, and the mean number of removed lymph nodes, as
documented by pathologists, was 10 (8e22). Metastases were re-
ported in up to 5 harvested lymph nodes.
4. Discussion
According to our data, inhering the management of PTC patients
without lymph nodal involvement, a low loco regional recurrence
rate, following TT not associated with routine LD, was observed. In
absence of suspected enlarged lymph node, identiﬁed by preoper-
ative ultrasonography and intraoperative inspection from the hyoid
bone to the sternal notch, patients undergoing TT without RCLD
have a low risk of lymph nodal recurrence. In the treatment of low-
risk PTC patients, routine LD is not indicated. Regarding recurrence,
male gender (a male/female ratio of 1/0.8) and a young age <50
years were the main clinical features, while follicular variant was
more frequently associated with lymph node relapse. The mean
size of the primary tumor was less than 2 cm, the central
compartment was largely affected, and the median elapsed time
between TT and lymph node recurrence was 28 months (12e82).
Unfortunately, BRAF mutations were not evaluated in these pa-
tients. Nevertheless, the small number of the examined cases, and
the lack of a control group of patients undergoing RCLD are the
main limitation of our analysis and suggest caution against gener-
alization of our assumptions.
Papillary variants are by far the most frequent thyroid neoplasm
[1,8], followed by follicular and medullary cancers, often part of the
MEN-2 syndrome [9]. Very rare and aggressive, anaplastic carci-
noma belongs to the group of killer tumors, with a very poor life
expectancy, as reported for carcinosarcoma of other districts [10].
Ultrasound (US) guided ﬁne-needle cytology (FNB) has allowed
a more precocious diagnosis [11,12] and PTC prognosis is favorable,
reﬂecting, with a low 10-year mortality rate and a long-term sur-
vival [13], the indolent nature of the neoplasm. However, in about
20% of patients, loco regional recurrences and PTC-related deaths
are still reported [14,15]. In a high percentage of cases, central or
lateral lymph nodal metastases are observed without a demon-
strated impact on survival, as well as the discordance between the
rate of lymph node micrometastases and the low incidence of
clinical recurrence, following TT without routine LD, is still subject
of research. Nevertheless, it must be considered that, especially in
older patients, lymphatic metastases may affect recurrence and
survival rates [14]. Multifocal primary tumor, inﬁltration of thyroid
capsule, patient age (pediatric or geriatric population), tumor size,
several oncogenes (p53, BRAF), are associated with node involve-
ment and are considered themain risk factors for recurrence [16]. It
is well known that male patients >45 years, with aggressive his-
totypes, capsular or loco regional inﬁltration, incomplete tumor
resection, BRAF positivity, are at high risk of loco regional anddistant recurrence. On the contrary, in the management of low-risk
patients, without suspected lymph node, TT is the operation of
choice, as in most thyroid diseases [17e20]. RCLD, with the aim of
providing a better chance of cure with a low morbidity, reducing
the recurrence risk, was strongly proposed in the last decade,
considering the high incidence of lymph node metastases, the
greater reoperation morbidity, the insufﬁcient diagnostic accuracy
of intraoperative inspection and of ultrasonography, and the failure
of 131I ablation in about 30% of cases. Nevertheless, it failed to
demonstrate beneﬁcial effects on recurrence and long-term sur-
vival, based on strong support data [21,22]. Certainly, prophylactic
LD may reduce postoperative Tg, favoring follow-up but increasing
the morbidity of thyroidectomies [22]. According to MLWhite et al.
[4], the rates of permanent hypoparathyroidism and of uninten-
tional permanent recurrent laryngeal nerve injury increased
respectively from 1 to 2% and 0e5.5% to 0e14.3% and 0e5.7%, in
case of RCLD associated with TT. This latter operation “alone”, fol-
lowed by RAI administration and TSH suppression therapy, may
guarantee a low incidence of loco regional lymph node recurrence,
and a long-term survival [23]. Regarding reoperation (lymph node
dissection) outcomes, a higher morbidity is not reported [24], as
conﬁrmed by Shen et al. [25], who did not observe signiﬁcant
beneﬁcial effects after TT combined with RCLD.
We believe that, in the treatment of PTC without suspicious
enlarged lymph node, it is not routinely indicated RCLD, as well as a
lateral prophylactic node dissection is never indicated. According to
ATA guide lines, RCLD is recommended in selected high risk cases
[2]. In low risk patients, a similar lymph nodal recurrence rate is
reported after TT without LD, reducing morbidity [26e30]. Ac-
cording to our experience, loco regional recurrences, mostly of the
central compartment, were more frequently observed 2 years after
TT in young male patients, sometimes affected by follicular variant,
in each case less than 2 cm. Considering the controversial literature
available data, more prospective randomized studies are needed in
the attempt to better deﬁne the impact of routine LD on loco
regional recurrence and long-term survival.
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